Loading...
Header Logo
Keywords
Last Name
Institution

Dr Apio Brenda Okech

TitleDirector
InstitutionUVRI-IAVI
AddressENTEBBE
Uganda
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Brenda Okech is the Director at UVRI-IAVI vaccine program in Entebbe, Uganda. UVRI-IAVI works with the fishing communities around Lake Victoria which is a key population in the fight against HIV.

    UVRI-IAVI HIV vaccine program has a vision of a world free of AIDS.

    Her major interests are in understanding natural immunity, Clinical Trials and prevention of Infectious Diseases like HIV and Malaria. Her long term goal is to have impact in reducing poverty through contributing to capacity building and promoting good health.

    She has experience in managing multiple country projects and was Project Manager for the EDCTP funded GMZ2 consortium for 5 years. The GMZ2 consortium involved a vaccine trial in 4 countries with partners from 7 countries. Brenda has over 20 years’ experience in human health research and management. Brenda has a PhD in Immunology from the London School of Hygiene and Tropical medicine.

    She had a TDR sponsored career development fellowship at Glaxo Smith Kline (GSK) in Belgium on Management of Clinical trials for 1 year. Brenda has previously worked with Med Biotech Laboratories Uganda, African Malaria Network Trust and Makerere University. She has also worked as a consultant for European Vaccine Initiative, Statens Serum Institute, Glaxo Smith Kline and TDR/WHO.


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Sirima SB, Mordmüller B, Milligan P, Ngoa UA, Kironde F, Atuguba F, Tiono AB, Issifou S, Kaddumukasa M, Bangre O, Flach C, Christiansen M, Bang P, Chilengi R, Jepsen S, Kremsner PG, Theisen M. A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children. Vaccine. 2016 08 31; 34(38):4536-4542. PMID: 27477844.
      View in: PubMed
    2. Kaddumukasa M, Buwembo W, Sekikubo M, Naiwumbwe H, Namusoke F, Kiwuwa S, Oketch B, Noor R, Chilengi R, Mworozi E, Kironde F. Malariometric indices from Iganga, Uganda: baseline characterization in preparation of GMZ2 vaccine trial. BMC Res Notes. 2014 Nov 08; 7:793. PMID: 25380673.
      View in: PubMed
    3. Swysen C, Vekemans J, Bruls M, Oyakhirome S, Drakeley C, Kremsner P, Greenwood B, Ofori-Anyinam O, Okech B, Villafana T, Carter T, Savarese B, Duse A, Reijman A, Ingram C, Frean J, Ogutu B. Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine. Malar J. 2011 Aug 04; 10:223. PMID: 21816032.
      View in: PubMed
    4. Bélard S, Issifou S, Hounkpatin AB, Schaumburg F, Ngoa UA, Esen M, Fendel R, de Salazar PM, Mürbeth RE, Milligan P, Imbault N, Imoukhuede EB, Theisen M, Jepsen S, Noor RA, Okech B, Kremsner PG, Mordmüller B. A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children. PLoS One. 2011; 6(7):e22525. PMID: 21829466.
      View in: PubMed
    5. Mujuzi G, Magambo B, Okech B, Egwang TG. Pigmented monocytes are negative correlates of protection against severe and complicated malaria in Ugandan children. Am J Trop Med Hyg. 2006 May; 74(5):724-9. PMID: 16687669.
      View in: PubMed
    6. Okech B, Mujuzi G, Ogwal A, Shirai H, Horii T, Egwang TG. High titers of IgG antibodies against Plasmodium falciparum serine repeat antigen 5 (SERA5) are associated with protection against severe malaria in Ugandan children. Am J Trop Med Hyg. 2006 Feb; 74(2):191-7. PMID: 16474069.
      View in: PubMed
    7. Okech BA, Corran PH, Todd J, Joynson-Hicks A, Uthaipibull C, Egwang TG, Holder AA, Riley EM. Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia. Infect Immun. 2004 Mar; 72(3):1557-67. PMID: 14977962.
      View in: PubMed
    8. Aoki S, Li J, Itagaki S, Okech BA, Egwang TG, Matsuoka H, Palacpac NM, Mitamura T, Horii T. Serine repeat antigen (SERA5) is predominantly expressed among the SERA multigene family of Plasmodium falciparum, and the acquired antibody titers correlate with serum inhibition of the parasite growth. J Biol Chem. 2002 Dec 06; 277(49):47533-40. PMID: 12244052.
      View in: PubMed
    9. Okech BA, Nalunkuma A, Okello D, Pang XL, Suzue K, Li J, Horii T, Egwang TG. Natural human immunoglobulin G subclass responses to Plasmodium falciparum serine repeat antigen in Uganda. Am J Trop Med Hyg. 2001 Dec; 65(6):912-7. PMID: 11791998.
      View in: PubMed
    Okech's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _